175 related articles for article (PubMed ID: 3190185)
1. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin.
Jones RN; Barry AL
Antimicrob Agents Chemother; 1988 Oct; 32(10):1576-82. PubMed ID: 3190185
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
Jones RN; Barry AL
Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
[TBL] [Abstract][Full Text] [Related]
3. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.
Bauernfeind A
Diagn Microbiol Infect Dis; 1991; 14(1):63-74. PubMed ID: 2013211
[TBL] [Abstract][Full Text] [Related]
4. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
Wise R; Andrews JM; Ashby JP; Thornber D
Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
[TBL] [Abstract][Full Text] [Related]
5. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.
Jones RN
Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S77-83. PubMed ID: 7567314
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807).
Jones RN; Barry AL
Antimicrob Agents Chemother; 1988 Apr; 32(4):443-9. PubMed ID: 3377457
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
Bauernfeind A; Jungwirth R
Infection; 1991; 19(5):353-62. PubMed ID: 1800377
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of ceftibuten, a new oral third generation cephalosporin.
Debbia EA; Schito GC; Pesce A
J Chemother; 1991 Aug; 3(4):209-25. PubMed ID: 1779255
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.
Barry AL; Pfaller MA; Fuchs PC; Packer RR
Antimicrob Agents Chemother; 1994 Oct; 38(10):2419-25. PubMed ID: 7840581
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720)--a review of United States and Canadian results.
Jones RN
Diagn Microbiol Infect Dis; 1991; 14(1):37-43. PubMed ID: 2013209
[TBL] [Abstract][Full Text] [Related]
11. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.
Jones RN; Barry AL
Eur J Clin Microbiol Infect Dis; 1988 Dec; 7(6):802-7. PubMed ID: 3145869
[TBL] [Abstract][Full Text] [Related]
12. LY164846 in vitro antimicrobial activity testing, including disk diffusion susceptibility tests using 30-microgram disks.
Jones RN; Baker C; Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1986 Mar; 29(3):530-4. PubMed ID: 3755018
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group.
Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810
[TBL] [Abstract][Full Text] [Related]
14. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial effects of the combination of ceftibuten and an orally absorbed penem SCH 29482.
Chin NX; Gu JW; Neu HC
Diagn Microbiol Infect Dis; 1991; 14(1):79-83. PubMed ID: 2013213
[TBL] [Abstract][Full Text] [Related]
16. Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.
Ayers LW; Jones RN; Barry AL; Thornsberry C; Fuchs PC; Gavan TL; Gerlach EH; Sommers HM
Antimicrob Agents Chemother; 1982 Nov; 22(5):859-77. PubMed ID: 6983862
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity and disk diffusion susceptibility testing of Ro 40-6890, the active metabolite of the new cephalosporin ester, Ro 41-3399.
Pfaller MA; Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1993 Apr; 37(4):893-5. PubMed ID: 8494387
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of interpretive criteria for Haemophilus influenzae by using meropenem (10-microgram), imipenem (10-microgram), and ampicillin (2- and 10-microgram) disks.
Zerva L; Biedenbach DJ; Jones RN
J Clin Microbiol; 1996 Aug; 34(8):1970-4. PubMed ID: 8818892
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.
Doern GV
Diagn Microbiol Infect Dis; 1991; 14(1):75-7. PubMed ID: 1901536
[TBL] [Abstract][Full Text] [Related]
20. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.
Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G
J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
